Bipartisan Senators Launch Probe Into Medicare Advantage AI Care Denials
A bipartisan pair of U.S. senators is demanding answers from Medicare Advantage insurers about their use of artificial intelligence in denying patient care claims.
Senators Richard Blumenthal (D-CT) and Josh Hawley (R-MO) have launched a joint probe examining how AI systems are being used to make coverage decisions for Medicare Advantage plans, which serve millions of American seniors. The investigation reflects growing congressional concern that automated algorithms may be inappropriately denying necessary medical care.
The senators are seeking documentation from major Medicare Advantage insurers about their AI-driven utilization management systems. Key areas of inquiry include how these algorithms are trained, what data they use to make denial decisions, and what oversight mechanisms exist to ensure patients are not wrongly denied coverage.
Healthcare advocates have long raised concerns that prior authorization requirements and coverage denials can delay or prevent seniors from receiving needed treatments. The use of AI in these decisions adds a new layer of complexity, as algorithmic systems may process thousands of claims without the nuanced understanding that human reviewers might provide.
The investigation comes amid broader scrutiny of AI deployment in healthcare, where the technology is increasingly used for everything from diagnostic imaging to treatment recommendations. Critics argue that while AI can improve efficiency, it should not be used as a cost-cutting mechanism that denies patients access to medically necessary care.
Industry representatives maintain that AI tools help ensure appropriate care and reduce administrative burdens, but critics contend that profit-driven insurers may prioritize cost savings over patient well-being when deploying such systems.
The senators have requested detailed information about denial rates, appeal processes, and the human oversight mechanisms in place when AI systems make coverage decisions. The outcome of this probe could lead to new regulatory requirements for how AI may be used in Medicare Advantage coverage determinations.